+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Abatacept decreases disease activity in a absence of CD4(+) T cells in a collagen-induced arthritis model



Abatacept decreases disease activity in a absence of CD4(+) T cells in a collagen-induced arthritis model



Arthritis Research and Therapy 17: 220



Abatacept is a fusion protein of human cytotoxic T-lymphocyte-associated protein (CTLA)-4 and the Fc portion of human immunoglobulin G1 (IgG1). It is believed to be effective in the treatment of rheumatoid arthritis by inhibiting costimulation of T cells via blocking CD28-B7 interactions as CTLA-4 binds to both B7.1 (CD80) and B7.2 (CD86). However, the interaction of CD28 with B7 molecules is crucial for activation of naive cells, whereas it is unclear whether the action of already activated CD4(+) T cells, which are readily present in established disease, also depends on this interaction. The aim of this study was to determine whether the mode of action of abatacept depends solely on its ability to halt T cell activation in established disease. Arthritis was induced in thymectomized male DBA/1 mice by immunisation with bovine collagen type II. The mice were subsequently depleted for CD4(+) T cells. Abatacept or control treatment was started when 80 % of the mice showed signs of arthritis. Arthritis severity was monitored by clinical scoring of the paws, and anti-collagen antibody levels over time were determined by enzyme-linked immunosorbent assay. Treatment with abatacept in the absence of CD4(+) T cells resulted in lower disease activity. This was associated with decreasing levels of collagen-specific IgG1 and IgG2a antibodies, whereas the antibody levels in control or CD4(+) T cell-depleted mice increased over time. These results show that abatacept decreased disease activity in the absence of CD4(+) T cells, indicating that the mode of action of abatacept in established arthritis does not depend entirely on its effects on CD4(+) T cell activation.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 057112205

Download citation: RISBibTeXText

PMID: 26290328

DOI: 10.1186/s13075-015-0731-1


Related references

THU0046Abatacept Decreases Disease Activity in the Absence of CD4+ T-Cells in the Collagen Induced Arthritis Model. Annals of the Rheumatic Diseases 74(Suppl 2): 208.3-209, 2015

Prophylactic administration of abatacept prevents disease and bone destruction in a rat model of collagen-induced arthritis. Journal of Autoimmunity 25(3): 165-171, 2005

Low disease activity in rheumatoid arthritis (RA) paitents treated with Abatacept in the aim (Abatacept in inadequate responders to methotrexate MTX) trial. 2006

An anti-murine IL-22 monoclonal antibody decreases disease severity in a murine model of collagen induced arthritis. European Cytokine Network 14(Suppl. 3): 129, 2003

Neutralisation of endogenous IL-18 activity is a disease-modifying therapy in the collagen-induced model of arthritis. Journal of Leukocyte Biology Suppl. ( ): 92, 2001

Moxibustion at mingmen reduces inflammation and decreases IL-6 in a collagen-induced arthritis mouse model. Journal of Acupuncture and Meridian Studies 5(1): 29-33, 2012

Clonal deletion of t cells decreases incidence of collagen induced arthritis. Arthritis & Rheumatism 33(9 Suppl.): S24, 1990

Interleukin-10-producing LAG3 + regulatory T cells are associated with disease activity and abatacept treatment in rheumatoid arthritis. Arthritis Research and Therapy 19(1): 97, 2017

Oestrogen induced suppression of collagen arthritis: I. Long term oestradiol treatment of DBA/1 mice reduces severity and incidence of arthritis and decreases the anti type II collagen immune response. Clinical and Experimental Immunology 70(2): 372-378, 1987

Modeling corticosteroid effects in a rat model of rheumatoid arthritis I: mechanistic disease progression model for the time course of collagen-induced arthritis in Lewis rats. Journal of Pharmacology and Experimental Therapeutics 326(2): 532-545, 2008

Pathogenic lymphoid cells engineered to express TGF beta-1 ameliorate disease in a collagen-induced arthritis model. Gene Therapy 4(6): 553-559, 1997

Mesenchymal stromal cells versus betamethasone can dampen disease activity in the collagen arthritis mouse model. Clinical and Experimental Medicine 14(3): 285-295, 2014

Combined Collagen-Induced Arthritis and Organic Dust-Induced Airway Inflammation to Model Inflammatory Lung Disease in Rheumatoid Arthritis. Journal of Bone and Mineral Research 34(9): 1733-1743, 2019

Anti-CD5 therapy decreases severity of established disease in collagen type II-induced arthritis in DBA/1 mice. Clinical & Experimental Immunology. 98(3): 442-447, 1994

α2β1 integrin regulates Th17 cell activity and its neutralization decreases the severity of collagen-induced arthritis. Journal of Immunology 191(12): 5941-5950, 2013